{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:26:46Z","timestamp":1790324806419,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T00:00:00Z","timestamp":1325116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00228-011-1198-x","type":"journal-article","created":{"date-parts":[[2011,12,28]],"date-time":"2011-12-28T09:23:00Z","timestamp":1325064180000},"page":"857-865","source":"Crossref","is-referenced-by-count":25,"title":["Do Parkinson\u2019s disease patients disclose their adverse events spontaneously?"],"prefix":"10.1007","volume":"68","author":[{"given":"Santiago","family":"Perez-Lloret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Ver\u00f3nica","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Ory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Spampinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,29]]},"reference":[{"issue":"Suppl 7","key":"1198_CR1","doi-asserted-by":"crossref","first-page":"VII2","DOI":"10.1007\/s00415-006-7002-7","volume":"253","author":"W Poewe","year":"2006","unstructured":"Poewe W (2006) The natural history of Parkinson\u2019s disease. J Neurol 253(Suppl 7):VII2\u2013VII6","journal-title":"J Neurol"},{"key":"1198_CR2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/01.wnl.0000223845.60960.d7","volume":"67","author":"RG Fariello","year":"2006","unstructured":"Fariello RG, Lieberman A (2006) Present and future approaches to Parkinson disease: from molecular insights to new therapeutic avenues. Neurology 67:S1\u2013S4","journal-title":"Neurology"},{"key":"1198_CR3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","volume":"20","author":"CG Goetz","year":"2005","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson\u2019s disease: 2001 to 2004. Mov Disord 20:523\u2013539","journal-title":"Mov Disord"},{"key":"1198_CR4","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/WNL.62.1_suppl_1.S39","volume":"62","author":"DJ Brooks","year":"2004","unstructured":"Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62:S39\u2013S46","journal-title":"Neurology"},{"key":"1198_CR5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/11537810-000000000-00000","volume":"24","author":"S Perez-Lloret","year":"2010","unstructured":"Perez-Lloret S, Rascol O (2010) Dopamine receptor agonists for the treatment of early or advanced Parkinson\u2019s disease. CNS Drugs 24:941\u2013968","journal-title":"CNS Drugs"},{"key":"1198_CR6","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1517\/14656566.6.12.2061","volume":"6","author":"O Rascol","year":"2005","unstructured":"Rascol O (2005) Rasagiline in the pharmacotherapy of Parkinson\u2019s disease\u2014a review. Expert Opin Pharmacother 6:2061\u20132075","journal-title":"Expert Opin Pharmacother"},{"key":"1198_CR7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","volume":"73","author":"JL Montastruc","year":"2006","unstructured":"Montastruc JL, Sommet A, Lacroix I, Olivier P, Durrieu G, Mase-Michel C, Lapeyre-Mestre M, Bagheri H (2006) Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 73:629\u2013632","journal-title":"Joint Bone Spine"},{"key":"1198_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385\u2013396","journal-title":"Drug Saf"},{"key":"1198_CR9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yebeh.2008.02.006","volume":"13","author":"M Carreno","year":"2008","unstructured":"Carreno M, Gil-Nagel A, Sanchez JC, Elices E, Serratosa JM, Salas-Puig J, Villanueva V, Porcel J (2008) Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav 13:178\u2013183","journal-title":"Epilepsy Behav"},{"key":"1198_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1198_CR11","volume-title":"Parkinson\u2019s disease and movement disorders","author":"J Jankovic","year":"2006","unstructured":"Jankovic J, Tolosa E (2006) Parkinson\u2019s disease and movement disorders, 5th edn. Lippincott Williams & Wilkins, London","edition":"5"},{"key":"1198_CR12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72:S1\u2013S136","journal-title":"Neurology"},{"key":"1198_CR13","unstructured":"Sweetman SC (2009) Martindale: the complete drug reference. www.medicinescomplete.com\/mc\/martindale\/current\/ . Accessed 1 June 2009"},{"key":"1198_CR14","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton RL, Members of the UPDRS committee (1987) Unified Parkinson\u2019s disease rating scale. In: Fahn S, Mardsen CD, Goldstein M (eds) Recent developments in Parkinson\u2019s disease, 2nd edn. McMillan, New York, pp 153\u2013163","edition":"2"},{"key":"1198_CR15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259","journal-title":"Lancet"},{"key":"1198_CR16","first-page":"111","volume":"40","author":"B Begaud","year":"1985","unstructured":"Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111\u2013118","journal-title":"Therapie"},{"issue":"Suppl 2","key":"1198_CR17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2008.02212.x","volume":"15","author":"KR Chaudhuri","year":"2008","unstructured":"Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 15(Suppl 2):2\u20137","journal-title":"Eur J Neurol"},{"key":"1198_CR18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/pds.1708","volume":"18","author":"N Jarernsiripornkul","year":"2009","unstructured":"Jarernsiripornkul N, Kakaew W, Loalukkana W, Krska J (2009) Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. Pharmacoepidemiol Drug Saf 18:240\u2013245","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1198_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.62.1.23","volume":"62","author":"FG Gilliam","year":"2004","unstructured":"Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H (2004) Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 62:23\u201327","journal-title":"Neurology"},{"key":"1198_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.22868","volume":"25","author":"KR Chaudhuri","year":"2010","unstructured":"Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, Ruessmann A, Odin P, Macphee G, Stocchi F, Ondo W, Sethi K, Schapira AH, Martinez Castrillo JC, Martinez-Martin P (2010) The nondeclaration of nonmotor symptoms of Parkinson\u2019s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:697\u2013701","journal-title":"Mov Disord"},{"key":"1198_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G, O\u2019Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423\u2013428","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1198_CR22","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","volume":"52","author":"S Frucht","year":"1999","unstructured":"Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908\u20131910","journal-title":"Neurology"},{"key":"1198_CR23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589\u2013595","journal-title":"Arch Neurol"},{"key":"1198_CR24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1468-1331.2006.01262.x","volume":"13","author":"JJ Ferreira","year":"2006","unstructured":"Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, Senard JM, Montastruc JL, Sampaio C, Rascol O (2006) Sleep disruption, daytime somnolence and \u2018sleep attacks\u2019 in Parkinson\u2019s disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 13:209\u2013214","journal-title":"Eur J Neurol"},{"key":"1198_CR25","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1468-1331.2010.03063.x","volume":"17","author":"PO Valko","year":"2010","unstructured":"Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR (2010) Fatigue and excessive daytime sleepiness in idiopathic Parkinson\u2019s disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol 17:1428\u20131436","journal-title":"Eur J Neurol"},{"key":"1198_CR26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540\u2013545","journal-title":"Sleep"},{"key":"1198_CR27","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1176\/appi.ajp.162.11.2184","volume":"162","author":"JE Grant","year":"2005","unstructured":"Grant JE, Levine L, Kim D, Potenza MN (2005) Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 162:2184\u20132188","journal-title":"Am J Psychiatry"},{"key":"1198_CR28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4103\/0253-7613.68437","volume":"42","author":"A Mandal","year":"2010","unstructured":"Mandal A, Chatterjee S, Das SK, Mishra A (2010) Drug safety monitoring in patients of movement disorders of a tertiary care hospital. Indian J Pharmacol 42:249\u2013251","journal-title":"Indian J Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-011-1198-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1198-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:48:56Z","timestamp":1558702136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1198-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,29]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1198-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,29]]}}}